Skip to content

Precise Phenotyping Classification in Atrial Fibrillation

Study on Precise Phenotyping Classification in Atrial Fibrillation

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07044011
Acronym
PPC-AF
Enrollment
1000
Registered
2025-06-29
Start date
2025-08-01
Completion date
2030-05-31
Last updated
2025-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, classification

Brief summary

This study aims to integrate multi-omics data (genomics, imaging, serology, etc.) to achieve precise phenotyping classification for atrial fibrillation (AF) patients and explore personalized rhythm control strategies. By enrolling over 1,000 AF patients, we will collect genomic data including GWAS and single-cell sequencing, combined with cardiac MRI, CT, echocardiography imaging, and serum biomarkers, to uncover AF pathological mechanisms and recurrence risks at molecular and structural levels. Machine learning and AI algorithms will be employed to develop AF phenotypic classification models, which will be validated across multiple centers to assess their accuracy and reliability in predicting AF recurrence and therapeutic responses. Furthermore, clinical trials will evaluate the efficacy of oral dronedarone hydrochloride tablets and intravenous nicorandil hydrochloride in preventing post-catheter ablation recurrence and their safety/effectiveness in early cardioversion. Finally, based on advanced phenotyping results, we will establish personalized rhythm control strategies integrating pharmacotherapy, catheter ablation, and lifestyle interventions to optimize AF management.

Interventions

None listed

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with atrial fibrillation. 2. Voluntarily participated in the study and signed the informed consent form.

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of atrial arrhythmia1 year after catheter ablation of atrial fibrillation.Atrial arrhythmia events lasting more than 30 seconds within 3 months to 1 year after catheter ablation of atrial fibrillation.

Countries

China

Contacts

Primary ContactLigang Ding Professor, Doctor
dlgang101@163.com+86 010-88322402

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026